Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Federico Caligaris‐Cappio et al.|New England Journal of Medicine|2014Cited by 1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, Jennifer R. Brown et al.|American Journal of Hematology|2019Cited by 472
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M. Horwitz, Pierluigi Porcu, Andrew D. Zelenetz et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 141
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphomaXuan J. Wang, Shaoying Li, L. Jeffrey Medeiros et al.|Modern Pathology|2016Cited by 92
Diffuse Large B-Cell Lymphoma Version 1.2016Andrew D. Zelenetz, Hema Sundar, Leo I. Gordon et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 87